Centene Q2 GAAP EPS $2.19, adj. EPS $2.51; raises 2026 guidance; board changes

CENTENE CORP

2026-Q2 EPS reported $5.30 revenue$103,523,000,000

Q2 GAAP diluted EPS $2.19, adjusted diluted EPS $2.51; total revenues $53.6B, premium & service revenues $44.4B.
Health benefits ratio improved to 89.6% from 93.0% YoY; Medicaid HBR 93.9%, Commercial 79.2%, Medicare 89.5%.
2026 guidance raised: GAAP diluted EPS >$3.11, adjusted diluted EPS >$4.80.
Board changes: Kenneth Burdick resigned; Paul Diaz appointed effective July 28, 2026. Diaz is former CEO of Myriad Genetics and Kindred Healthcare.
Repurchased $260M of senior notes due 2027/2028; total debt $16.1B; cash from operations $3.6B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.